deltatrials
Completed PHASE2 NCT00448760

Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery

A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma

Sponsor: University of Miami

Conditions Esophageal Cancer
Interventions Conventional surgery Docetaxel Floxuridine Leucovorin Microarray analysis Oxaliplatin reverse transcriptase-polymerase chain reaction
Updated 6 times since 2017 Last updated: Dec 14, 2016 Started: Oct 31, 2004 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

Listed as NCT00448760, this PHASE2 trial focuses on Esophageal Cancer and remains completed. Sponsored by University of Miami, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Miami
Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Miami, United States